Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Rosuvastatin can raise liver enzymes and slightly increase the risk of new-onset type 2 diabetes, though serious liver injury is rare and most people tolerate the drug well. Risk factors such as pre-existing liver disease, heavy alcohol use, higher doses, prediabetes, and obesity influence how likely these effects are. Warning signs worth attention include unusual fatigue, dark urine, yellowing of the eyes or skin, upper right abdominal pain, increased thirst, or frequent urination. For most patients, the cardiovascular benefit of lowering cholesterol outweighs these risks, but there are several important factors to consider before stopping or continuing treatment, so see below to understand more.
If you are noticing new symptoms while taking rosuvastatin, it helps to know whether they point toward a liver issue, blood sugar changes, or something unrelated to the medication entirely. A free, instant, online symptom check lets you describe what you are feeling in a few minutes and receive tailored insight into possible causes, plus guidance on how urgently to speak with a clinician. That clarity can help you avoid unnecessary worry, prepare better questions for your doctor, and make sure a treatable problem is not overlooked.
Last reviewed for medical accuracy: 09/12/2026
Rosuvastatin is a widely prescribed statin medication used to lower “bad” LDL cholesterol and reduce the risk of heart attack, stroke, and other cardiovascular events. Like any medication, it carries potential side effects. Two concerns often raised are liver injury and the chance of developing diabetes. This guide reviews the evidence, outlines warning signs, and offers practical advice—all in clear, reassuring language.
Rosuvastatin belongs to the statin class of drugs. It:
By improving your cholesterol numbers and vessel health, rosuvastatin cuts your overall cardiovascular risk.
If enzyme levels exceed three times the upper limit of normal, your doctor may adjust your dose or switch you to a different therapy.
Knowing what to watch for helps ensure any rare problem is caught early.
Possible liver-related symptoms:
Possible elevated blood sugar/diabetes signs:
If you notice any of these symptoms—or simply feel something isn’t right—consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help decide if prompt medical attention is needed.
Discuss rosuvastatin with your doctor if you have:
Your doctor will tailor your dose, monitor labs, and recommend lifestyle changes to keep you safe.
Contact your doctor right away if you experience:
Always discuss any serious or life-threatening concerns—never wait.
Rosuvastatin is a powerful tool to reduce cardiovascular risk. While mild liver enzyme elevations are relatively common, serious liver damage is rare. There is a small increased chance of developing diabetes, but for most people at risk of heart disease, the benefits outweigh the risks. Monitoring and open communication with your doctor are essential for safe, effective treatment.
If you’re ever unsure about symptoms or side effects, a free, online symptom check, using the doctor approved Ubie Symptom Checker can help you decide whether to seek medical care.
Always talk with your healthcare provider about any concerns or serious symptoms. Your doctor will guide you in balancing the risks and rewards of rosuvastatin to protect your heart health without compromising your well-being.
(References)
* Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9. PMID: 18997196.
* Kaufman KR, Podolsky D, Greenman D, Madraswala R. Antidepressant-selective gynecomastia. Ann Pharmacother. 2013 Jan;47(1):e6. doi: 10.1345/aph.1R491. Epub 2013 Jan 16. PMID: 23324513.
* Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJ, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sanchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Diaz R, Lonn E, HOPE-3 Investigators. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016 May 26;374(21):2021-31. doi: 10.1056/NEJMoa1600176. Epub 2016 Apr 2. PMID: 27040132.
* Casula M, Mozzanica F, Scotti L, Tragni E, Pirillo A, Corrao G, Catapano AL. Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2017 May;27(5):396-406. doi: 10.1016/j.numecd.2017.03.001. Epub 2017 Mar 10. PMID: 28416099.
* Zhang X, Xing L, Jia X, Pang X, Xiang Q, Zhao X, Ma L, Liu Z, Hu K, Wang Z, Cui Y. Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials. Cardiovasc Ther. 2020;2020:3987065. doi: 10.1155/2020/3987065. Epub 2020 Apr 23. PMID: 32411300; PMCID: PMC7201823.
* Hodkinson A, Tsimpida D, Kontopantelis E, Rutter MK, Mamas MA, Panagioti M. Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis. BMJ. 2022 Mar 24;376:e067731. doi: 10.1136/bmj-2021-067731. Epub 2022 Mar 24. PMID: 35331984; PMCID: PMC8943592.
* Lee YJ, Hong SJ, Kang WC, Hong BK, Lee JY, Lee JB, Cho HJ, Yoon J, Lee SJ, Ahn CM, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK, LODESTAR investigators. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. BMJ. 2023 Oct 18;383:e075837. doi: 10.1136/bmj-2023-075837. Epub 2023 Oct 18. PMID: 37852649; PMCID: PMC10583134.
* Malani SK, Chigullapalli S, Sujanyal S, Sharma V. Rosuvastatin-Induced Myopathy: A Case Series. Cureus. 2024 Aug;16(8):e66180. doi: 10.7759/cureus.66180. Epub 2024 Aug 5. PMID: 39233949; PMCID: PMC11373368.
* Zhou S, Chen R, Liu J, Guo Z, Su L, Li Y, Zhang X, Luo F, Gao Q, Lin Y, Pang M, Cao L, Xu X, Nie S. Comparative Effectiveness and Safety of Atorvastatin Versus Rosuvastatin : A Multi-database Cohort Study. Ann Intern Med. 2024 Dec;177(12):1641-1651. doi: 10.7326/M24-0178. Epub 2024 Oct 29. PMID: 39467290.
* Cha JJ, Shin Y, Joo HJ, Park JH, Yu CW, Lee PH, Lee SW, Lee CW, Moon JY, Lee JY, Kim JS, Park JS, Hong SJ. Metabolic and Safety Outcomes of Statin-Ezetimibe Versus High-Intensity Statin in Older Patients. J Am Heart Assoc. 2026 Jul 7;15(13):e048711. doi: 10.1161/JAHA.125.048711. Epub 2026 Jul 3. PMID: 42396798; PMCID: PMC13477364.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.